Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders

Blood Reviews

Volumn 23, Issue 4, 2009, Pages 157-165

  Valent, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Chronic eosinophilic leukemia; Eosinophils; PDGF receptors; Targeted drugs

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; ALPHA INTERFERON; BRIVANIB; DASATINIB; HYDROXYUREA; IMATINIB; MIDOSTAURIN; MOLECULAR MARKER; NILOTINIB; ONCOPROTEIN; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TKI 258; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ARTICLE; BLOOD EXAMINATION; BONE MARROW; BONE MARROW BIOPSY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG DOSE ESCALATION; DRUG TARGETING; EOSINOPHIL; EOSINOPHIL COUNT; EOSINOPHILIA; EOSINOPHILIC LEUKEMIA; GENE MUTATION; HEART MUSCLE FIBROSIS; HEMATOLOGIC MALIGNANCY; HISTOPATHOLOGY; HUMAN; HYPEREOSINOPHILIC SYNDROME; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MAST CELL; MAST CELL LEUKEMIA; MASTOCYTOMA; MASTOCYTOSIS; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

CYTOKINES; EOSINOPHILIA; EOSINOPHILS; HEMATOLOGIC NEOPLASMS; HUMANS; MASTOCYTOSIS; MYELOPROLIFERATIVE DISORDERS;

EID: 67349151349     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2009.01.001     Document Type: Article

References (74)

1. Gleich G.J., Adolphson C.R., and Leiferman K.M. The biology of the eosinophilic leukocyte. Annu Rev Med 44 (1993) 85-101
2. Weller P.F. Eosinophils: structure and functions. Curr Opin Immunol 6 (1994) 85-90
3. Gleich G.J. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 105 (2000) 651-663
4. Hogan S.P., Rosenberg H.F., Moqbel R., Phipps S., Foster P.S., Lacy P., et al. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy 38 (2008) 709-750
5. Ackerman S.J., and Bochner B.S. Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. Immunol Allergy Clin N Am 27 (2007) 357-375
6. Ogbogu P.U., Rosing D.R., and Horne III M.K. Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin N Am 27 (2007) 457-475
7. Leary A.G., and Ogawa M. Identification of pure and mixed basophil colonies in culture of human peripheral blood and marrow cells. Blood 64 (1984) 78-83
8. Denburg J.A., Telizyn S., Messner H., Lim B., Jamal N., Ackerman S.J., et al. Heterogeneity of human peripheral blood eosinophil-type colonies: evidence for a common basophil-eosinophil progenitor. Blood 66 (1985) 312-318
9. Huang S., and Terstappen L.W. Lymphoid and myeloid differentiation of single human CD34+, HLA-DR+, CD38- hematopoietic stem cells. Blood 83 (1994) 1515-1526
10. Shalit M., Sekhsaria S., Mauhorter S., Mahanti S., and Malech H.L. Early commitment to the eosinophil lineage by cultured human peripheral blood CD34+ cells: messenger RNA analysis. J Allergy Clin Immunol 98 (1996) 344-354
11. Denburg J.A. Hemopoietic progenitors and cytokines in allergic inflammation. Allergy 53 (1998) 22-26
12. Linden M., Svensson C., Andersson M., Greiff L., Andersson E., Denburg J.A., et al. Circulating eosinophil/basophil progenitors and nasal mucosal cytokines in seasonal allergic rhinitis. Allergy 54 (1999) 212-219
13. Clutterbuck E., Shields J.G., Gordon J., Smith S.H., Boyd A., Callard R.E., et al. Recombinant human interleukin 5 is an eosinophil differentiation factor but has no activity in standard human B cell growth factor assays. Eur J Immunol 17 (1987) 1743-1750
14. Saito H., Hatake K., Dvorak A.M., Leiferman K.M., Donnenberg A.D., Arai N., et al. Selective differentiation and proliferation of hematopoietic cells induced by recombinant human interleukins. Proc Natl Acad Sci USA 85 (1988) 2288-2292
15. Valent P., Schmidt G., Besemer J., Mayer P., Zenke G., Liehl E., et al. Interleukin-3 is a differentiation factor for human basophils. Blood 73 (1989) 1763-1769
16. Feldmann M., Londei M., and Haworth C. T cells and lymphokines. Br Med Bull 45 (1989) 361-370
17. Del Prete G. Human Th1 and Th2 lymphocytes: their role in the pathophysiology of atopy. Allergy 47 (1992) 450-455
18. Denburg J.A. Microenvironmental influences on inflammatory cell differentiation. Allergy 50 (1995) 25-28
19. Shakoory B., Fitzgerald S.M., Lee S.A., Chi D.S., and Krishnaswamy G. The role of human mast cell-derived cytokines in eosinophil biology. J Interferon Cytokine Res 24 (2004) 271-281
20. Lopez A.F., Vadas M.A., Woodcock J.M., Milton S.E., Lewis A., Elliott M.J., et al. Interleukin-5, interleukin-3, and granulocyte-macrophage colony-stimulating factor cross-compete for binding to cell surface receptors on human eosinophils. J Biol Chem 266 (1991) 24741-24747
21. Lopez A.F., Elliott M.J., Woodcock J., and Vadas M.A. GM-CSF, IL-3 and IL-5: cross-competition on human haemopoietic cells. Immunol Today 13 (1992) 495-500
22. Kay A.B. The eosinophil in infection diseases. J Infect Dis 129 (1974) 606-613
23. Tas S., and Simonart T. Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update. Dermatology 206 (2003) 353-356
24. Sade K., Mysels A., Levo Y., and Kivity S. Eosinophilia: a study of 100 hospitalized patients. Eur J Intern Med 18 (2007) 196-201
25. Tefferi A., Patnaik M.M., and Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 133 (2006) 468-492
26. Mahmoud A.A. The ecology of eosinophils in schistosomiasis. J Infect Dis 145 (1982) 613-622
27. Kargili A., Bavbek N., Kaya A., Koşar A., and Karaaslan Y. Eosinophilia in rheumatologic diseases: a prospective study of 1000 cases. Rheumatol Int 24 (2004) 321-324
28. Lotfi R., Lee J.J., and Lotze M.T. Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. J Immunother 30 (2007) 16-28
29. Nutman T.B. Evaluation and differential diagnosis of marked, persistent eosinophilia. Immunol Allergy Clin N Am 27 (2007) 529-549
30. Simon D., and Simon H.U. Eosinophilic disorders. J Allergy Clin Immunol 119 (2007) 1291-1300
31. Klion A.D., Bochner B.S., Gleich G.J., Nutman T.B., Rothenberg M.E., Simon H.U., et al. The hypereosinophilic syndromes working group. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 117 (2006) 1292-1302
32. Roufosse F.E., Goldman M., and Cogan E. Hypereosinophilic syndromes. Orphanet J Rare Dis 2 (2007) 37
33. Bain B.J. Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome. Br J Haematol 95 (1996) 2-9
34. Gotlib J., Cross N.C., and Gilliland D.G. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. Best Pract Res Clin Haematol 19 (2006) 535-569
35. Haferlach T., Bacher U., Kern W., Schnittger S., and Haferlach C. The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers. Ann Hematol 87 (2008) 1-10
36. Valent P., Horny H.P., Escribano L., Longley B.J., Li C.Y., Schwartz L.B., et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 25 (2001) 603-625
37. Valent P., Akin C., Escribano L., Födinger M., Hartmann K., Brockow K., et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 37 (2007) 435-453
38. Bain B.J., and Fletcher S.H. Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. Immunol Allergy Clin N Am 27 (2007) 377-388
39. Fletcher S., and Bain B. Eosinophilic leukaemia. Br Med Bull 81-82 (2007) 115-127
40. Tefferi A., and Vardiman J.W. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22 (2008) 14-22
41. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348 (2003) 1201-1214
42. Pardanani A., Ketterling R.P., Brockman S.R., Flynn H.C., Paternoster S.F., Shearer B.M., et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 102 (2003) 3093-3096
43. Apperley J.F., Gardembas M., Melo J.V., Russell-Jones R., Bain B.J., Baxter E.J., et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347 (2002) 481-487
44. Pardanani A., Reeder T., Porrata L.F., Li C.Y., Tazelaar H.D., Baxter E.J., et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 101 (2003) 3391-3397
45. Tefferi A. Modern diagnosis and treatment of primary eosinophilia. Acta Haematol 114 (2005) 52-60
46. Wang L.N., Pan Q., Fu J.F., Shi J.Y., Jin J., Li J.M., et al. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib. Chin Med J 121 (2008) 867-873
47. Burgstaller S., Kreil S., Waghorn K., Metzgeroth G., Preudhomme C., Zoi K., et al. The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus. Leukemia 21 (2007) 2428-2432
48. Yamada Y., Rothenberg M.E., Lee A.W., Akei H.S., Brandt E.B., Williams D.A., et al. The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease. Blood 107 (2006) 4071-4079
49. Wimazal F., Baumgartner C., Sonneck K., Zauner C., Geissler P., Schur S., et al. Mixed-lineage eosinophil/basophil crisis in MDS: a rare form of progression. Eur J Clin Invest 38 (2008) 447-455
50. Matsushima T., Handa H., Yokohama A., Nagasaki J., Koiso H., Kin Y., et al. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood 101 (2003) 3386-3390
51. Hauswirth A.W., Sperr W.R., Ghannadan M., Schernthaner G.H., Jordan J.H., Fritsche-Polanz R., et al. A case of smouldering mastocytosis with peripheral blood eosinophilia and lymphadenopathy. Leuk Res 26 (2002) 601-606
52. Böhm A., Födinger M., Wimazal F., Haas O.A., Mayerhofer M., Sperr W.R., et al. Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance. J Allergy Clin Immunol 120 (2007) 192-199
53. Metcalfe D.D. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol 96 (1991) 2S-4S
54. Akin C. Multilineage hematopoietic involvement in systemic mastocytosis. Leuk Res 27 (2003) 877-878
55. Pardanani A., Reeder T., Li C.Y., and Tefferi A. Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leuk Res 27 (2003) 883-885
56. Bain B.J. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. Am J Hematol 77 (2004) 82-85
57. Valent P., Akin C., and Metcalfe D.D. FIP1L1/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosis. Eur J Clin Invest 37 (2007) 153-154
58. Simon H.U., Plötz S.G., Dummer R., and Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 341 (1999) 1112-1120
59. Roufosse F., Schandené L., Sibille C., Willard-Gallo K., Kennes B., Efira A., et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol 109 (2000) 540-548
60. Bain B., Gilliland D.G., Vardiman J.W., and Horny H.P. Chronic eosinophilic leukaemia, not otherwise specified. In: Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., Thiele J., and Vardiman J.W. (Eds). WHO classification of tumours of haematopoietic and lymphoid tissues vol. 2 (2008), WHO Press, Geneva (Switzerland) and Albany (NY, USA) 51-53
61. Bain B., Gilliland D.G., Horny H.P., and Vardiman J.W. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1. In: Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., Thiele J., and Vardiman J.W. (Eds). WHO classification of tumours of haematopoietic and lymphoid tissues vol. 2 (2008), WHO Press, Geneva (Switzerland) and Albany (NY, USA) 68-73
62. Tefferi A. Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment. Mayo Clin Proc 80 (2005) 75-83
63. Stover E.H., Chen J., Lee B.H., Cools J., McDowell E., Adelsperger J., et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood 106 (2005) 3206-3213
64. Baumgartner C., Gleixner K.V., Peter B., Ferenc V., Gruze A., Remsing-Rix L.L., et al. Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRα. Exp Hematol 36 (2008) 1244-1253
65. Verstovsek S., Tefferi A., Cortes J., O'Brien S., Garcia-Manero G., Pardanani A., et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 14 (2008) 3906-3915
66. Cools J., Stover E.H., Boulton C.L., Gotlib J., Legare R.D., Amaral S.M., et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell 3 (2003) 459-469
67. Lierman E., Folens C., Stover E.H., Mentens N., Van Miegroet H., Scheers W., et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 108 (2006) 1374-1376
68. von Bubnoff N., Gorantla S.P., Thöne S., Peschel C., and Duyster J. The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib). Blood 107 (2006) 4970-4971
69. Reiter A., Grimwade D., and Cross N.C. Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders. Haematologica 92 (2007) 1153-1158
70. Verstovsek S., Tefferi A., Kantarjian H., Manshouri T., Luthra R., Pardanani A., et al. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res 15 (2009) 368-373
71. Kalac M., Quintás-Cardama A., Vrhovac R., Kantarjian H., and Verstovsek S. A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. Cancer 110 (2007) 955-964
72. Jovanovic J.V., Score J., Waghorn K., Cilloni D., Gottardi E., Metzgeroth G., et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 109 (2007) 4635-4640
73. Gotlib J., and Cools J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 22 (2008) 1999-2010
74. Rothenberg M.E., Klion A.D., Roufosse F.E., Kahn J.E., Weller P.F., Simon H.U., et al. Mepolizumab HES study group. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 358 (2008) 1215-1228